Zobrazeno 1 - 10
of 25
pro vyhledávání: '"T A W, Splinter"'
Publikováno v:
Scandinavian Journal of Haematology. 20:29-36
A case report is presented of a 77-year-old woman suffering from a composite lymphoma, known as Richter's Syndrome, consisting of chronic lymphocytic leukaemia (CLL) and diffuse histiocytic lymphoma. Light-microscopic investigation revealed the prese
Autor:
Tarek Sahmoud, J. Burghouts, Desmond Curran, G. Giaccone, F. Gozzelino, Anne Kirkpatrick, Pe Postmus, Giorgio V. Scagliotti, Harry J.M. Groen, T. A. W. Splinter
Publikováno v:
Scopus-Elsevier
European Journal of Cancer, 32A(9), 1498-1503. ELSEVIER SCI LTD
European Journal of Cancer, 32A(9), 1498-1503. ELSEVIER SCI LTD
Alternating chemotherapy for small cell lung cancer has been tested in several studies. Some have shown positive results that have not been confirmed in other studies. In all of the studies, however, the degree of non-cross-resistance in the regimens
Autor:
J. Genolla, S. A. Gomm, M. Szturmowicz, K. Østerlind, J. R. Hernandez, L. G. M. Jørgensen, T. A. W. Splinter, J. Løber, Peter Johnson
Publikováno v:
British Journal of Cancer
The influence of pretreatment serum neuron-specific enolase (S-NSE) in addition to more conventional prognostic factors on survival duration in small-cell lung cancer (SCLC) was investigated in 770 patients from nine centres in six countries. The oth
Autor:
T. Conroy, P. Cappelaere, M. Fabbro, A. A. Fauser, T. A. W. Splinter, M. Spielmann, M. Schneider, B. Chevallier, A. Goupil, J. Chauvergne, P. Fargeot, G. Prévot, P. OʼGrady, D. Green, J. Hardenberg, M. Boyce
Publikováno v:
American Journal of Clinical Oncology. 17:97-102
Dolasetron mesylate (MDL 73,147EF), a new serotonin receptor (5-HT3) antagonist was administered to 164 cancer patients naive or non-naive to chemotherapy, in single, rising doses of 10, 20, 30, 40, or 50 mg i.v. 15 minutes prior to an infusion of ci
Autor:
T. A. W. Splinter, A. Van De Gaast, C. F. Verkoelen, F. Boomsma, M. Vlastuin, G. Rijksen, T. C. Kok, K. G. Haglid
Publikováno v:
British Journal of Cancer
Neuron specific enolase (NSE) is widely used as a neuro-endocrine marker. However the presence of NSE in many non-neuroendocrine tissues has raised questions on the specificity of NSE. We have investigated NSE immunoreactivity (NSA-ag), gamma-enolase
Autor:
T A W, Splinter
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 150(49)
Newly graduated doctors must be able to solve a limited number of patient-specific problems in an adequate manner. The patient is at the centre of attention here, not the doctor. Accepting religious beliefs and cultural differences as an excuse for n
Publikováno v:
British Journal of Haematology. 88:196-198
Summary. We report a patient who developed acute myeloid leukaemia (M2) shortly after successful treatment of a mediastinal germ cell tumour. The leukaemia was preceded by a documented myelodysplastic phase. Complex cytogenetic abnormalities were fou
Autor:
T. A. W. Splinter
Publikováno v:
Tijdschrift voor Medisch Onderwijs. 28:132-133
De onderwijswereld roert zich hevig. Het gemeenschappelijke onderwerp van aandacht is de verschuiving van ‘docentgericht’ naar ‘studentgericht’ onderwijs. Deze verschuiving herkent men aan termen zoals het zeer populaire ‘problem based lear
Publikováno v:
Medical Radiology ISBN: 9783642643231
Survival in untreated patients with metastatic carcinoma of the bladder is poor, the median survival being 3 months (Babaian et al. 1980). The current therapy of choice is combination chemotherapy, which is given with palliative intent, although some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de7f98a119666bbb5e044300a1aba25d
https://doi.org/10.1007/978-3-642-60258-0_28
https://doi.org/10.1007/978-3-642-60258-0_28
Autor:
H.M. Pinedo, K. J. Vendrik, T. A. W. Splinter, A. van Oosterom, M. E. L. Van Der Burg, W.W. ten Bokkel Huinink, D. T. H. Sleijfer, B. C. Tanis, E. van der Putten, Jan B. Vermorken
Publikováno v:
Oncology
Spiroplatin was investigated in a multicenter phase II study, during which the drug was given over 4 h. 64 Patients with nine different solid tumors received 141 cycles of spiroplatin at a dose of 30 mg/m2 every 3 weeks. Most important side effects i